Galectin Therapeutics (GALT) Competitors $1.42 +0.08 (+5.97%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GALT vs. OLMA, BNTC, CMPS, TKNO, ALLO, TRDA, ARCT, TSHA, HRTX, and ATYRShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Olema Pharmaceuticals (OLMA), Benitec Biopharma (BNTC), COMPASS Pathways (CMPS), Alpha Teknova (TKNO), Allogene Therapeutics (ALLO), Entrada Therapeutics (TRDA), Arcturus Therapeutics (ARCT), Taysha Gene Therapies (TSHA), Heron Therapeutics (HRTX), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. Olema Pharmaceuticals Benitec Biopharma COMPASS Pathways Alpha Teknova Allogene Therapeutics Entrada Therapeutics Arcturus Therapeutics Taysha Gene Therapies Heron Therapeutics Atyr PHARMA Olema Pharmaceuticals (NASDAQ:OLMA) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking. Does the MarketBeat Community favor OLMA or GALT? Galectin Therapeutics received 311 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. However, 70.59% of users gave Olema Pharmaceuticals an outperform vote while only 59.01% of users gave Galectin Therapeutics an outperform vote. CompanyUnderperformOutperformOlema PharmaceuticalsOutperform Votes3670.59% Underperform Votes1529.41% Galectin TherapeuticsOutperform Votes34759.01% Underperform Votes24140.99% Do institutionals & insiders hold more shares of OLMA or GALT? 91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 19.4% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 50.1% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is OLMA or GALT more profitable? Galectin Therapeutics' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Olema PharmaceuticalsN/A -53.56% -47.86% Galectin Therapeutics N/A N/A -163.15% Which has better valuation and earnings, OLMA or GALT? Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOlema PharmaceuticalsN/AN/A-$96.65M-$2.21-2.29Galectin TherapeuticsN/AN/A-$41.07M-$0.76-1.83 Does the media favor OLMA or GALT? In the previous week, Olema Pharmaceuticals had 6 more articles in the media than Galectin Therapeutics. MarketBeat recorded 6 mentions for Olema Pharmaceuticals and 0 mentions for Galectin Therapeutics. Olema Pharmaceuticals' average media sentiment score of 1.71 beat Galectin Therapeutics' score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Olema Pharmaceuticals Very Positive Galectin Therapeutics Neutral Which has more volatility and risk, OLMA or GALT? Olema Pharmaceuticals has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Do analysts rate OLMA or GALT? Olema Pharmaceuticals presently has a consensus price target of $27.67, indicating a potential upside of 446.56%. Galectin Therapeutics has a consensus price target of $11.00, indicating a potential upside of 693.08%. Given Galectin Therapeutics' higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than Olema Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Olema Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Galectin Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryOlema Pharmaceuticals beats Galectin Therapeutics on 8 of the 15 factors compared between the two stocks. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.19M$6.57B$5.40B$7.68BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-1.897.0922.2118.29Price / SalesN/A263.59392.81105.26Price / CashN/A65.6738.2034.62Price / Book-1.376.396.774.22Net Income-$41.07M$142.49M$3.21B$247.51M7 Day Performance0.51%7.35%4.84%5.54%1 Month Performance-15.94%-8.25%-6.33%-4.23%1 Year Performance-57.84%-1.81%16.11%4.29% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics0.911 of 5 stars$1.42+6.0%$11.00+674.6%-60.0%$89.72MN/A-1.959OLMAOlema Pharmaceuticals2.7177 of 5 stars$4.75+7.5%$27.67+482.5%-49.6%$324.58MN/A-2.1770News CoveragePositive NewsBNTCBenitec Biopharma2.4854 of 5 stars$13.80+0.4%$24.71+79.1%+99.1%$323.62M$80,000.00-9.1420Positive NewsCMPSCOMPASS Pathways2.3009 of 5 stars$3.38+8.0%$20.20+497.6%-52.1%$313.24MN/A-1.54120News CoveragePositive NewsTKNOAlpha Teknova1.4485 of 5 stars$5.78+0.3%$8.50+47.1%+267.4%$308.87M$37.75M-7.81240News CoverageALLOAllogene Therapeutics2.964 of 5 stars$1.42-2.1%$9.29+554.1%-52.2%$308.52M$22,000.00-0.91310News CoverageTRDAEntrada Therapeutics2.8146 of 5 stars$7.95-2.2%$25.67+222.9%-32.4%$298.88M$210.78M5.00110Positive NewsHigh Trading VolumeARCTArcturus Therapeutics2.8033 of 5 stars$11.00+4.5%$59.20+438.2%-54.7%$298.32M$138.39M-4.95180TSHATaysha Gene Therapies3.2198 of 5 stars$1.45+16.9%$6.63+356.9%-28.1%$297.33M$8.33M2.30180News CoveragePositive NewsHRTXHeron Therapeutics3.3448 of 5 stars$1.93+4.9%$5.67+193.6%-21.3%$294.00M$144.29M-10.72300News CoveragePositive NewsATYRAtyr PHARMA2.2344 of 5 stars$3.28+5.8%$18.60+467.1%N/A$291.46M$235,000.00-3.4953Upcoming Earnings Related Companies and Tools Related Companies OLMA Alternatives BNTC Alternatives CMPS Alternatives TKNO Alternatives ALLO Alternatives TRDA Alternatives ARCT Alternatives TSHA Alternatives HRTX Alternatives ATYR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GALT) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Intuitive Surgical at $1.99. Nvidia at $11. Shorting Fannie Mae months before collapse. That’s this analyst’s ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GALT Stock Free GALT Stock Alerts